Aurobindo Pharma Share Price
Sector: Major Drugs
1201.85 -15.15 (-1.24%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1197.00
Today’s High
1233.65
52 Week Low
994.35
52 Week High
1592.55
1201.20 -15.70 (-1.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1197.00
Today’s High
1225.40
52 Week Low
1010.00
52 Week High
1592.00
Key Metrics
- Market Cap (In Cr) 69803.65
- Beta 0.75
- Div. Yield (%) 0
- P/B 2.36
- TTM P/E 22.31
- Sector P/E 24.5
- Open Price 1233.65
- Prev Close 1217
Aurobindo Pharma Analysis
Price Analysis
-
1 Week3.16%
-
3 Months6.17%
-
6 Month-3.83%
-
YTD-9.99%
-
1 Year3.56%
Risk Meter
- 34% Low risk
- 34% Moderate risk
- 34% Balanced Risk
- 34% High risk
- 34% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 11
- 10
- 10
- 10
- Buy
- 9
- 9
- 9
- 10
- Hold
- 1
- 2
- 2
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 25
- 25
- 25
- 26
Aurobindo Pharma News
Aurobindo Pharma shares fall over 3% after fire incident at its facility
1 min read . 29 Apr 2025Stocks to watch: Bajaj Finance, Ultratech Cement among shares in focus today
2 min read . 29 Apr 2025Aurobindo Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 29001.87
- Selling/ General/ Admin Expenses Total
- 8858.87
- Depreciation/ Amortization
- 1491.91
- Other Operating Expenses Total
- 530.61
- Total Operating Expense
- 24871.4
- Operating Income
- 4130.47
- Net Income Before Taxes
- 4379.99
- Net Income
- 3172.97
- Diluted Normalized EPS
- 57
- Period
- 2024
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.74
- Period
- 2024
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023
- Total Revenue
- 24855.38
- Selling/ General/ Admin Expenses Total
- 8189.45
- Depreciation/ Amortization
- 1244.58
- Other Operating Expenses Total
- 518.34
- Total Operating Expense
- 22341.74
- Operating Income
- 2513.64
- Net Income Before Taxes
- 2612.5
- Net Income
- 1927.5
- Diluted Normalized EPS
- 33.03
- Period
- 2023
- Total Assets
- 39889.99
- Total Liabilities
- 13050.14
- Total Equity
- 26839.85
- Tangible Book Valueper Share Common Eq
- 391.13
- Period
- 2023
- Cashfrom Operating Activities
- 2393.16
- Cashfrom Investing Activities
- -3977.75
- Cashfrom Financing Activities
- 1814.41
- Net Changein Cash
- 229.76
- Period
- 2022
- Total Revenue
- 23455.49
- Selling/ General/ Admin Expenses Total
- 7593.01
- Depreciation/ Amortization
- 1126.52
- Other Operating Expenses Total
- 316.95
- Total Operating Expense
- 20399.22
- Operating Income
- 3056.27
- Net Income Before Taxes
- 3372.74
- Net Income
- 2648.15
- Diluted Normalized EPS
- 47.45
- Period
- 2022
- Total Assets
- 33921.72
- Total Liabilities
- 9345.74
- Total Equity
- 24575.98
- Tangible Book Valueper Share Common Eq
- 357.76
- Period
- 2022
- Cashfrom Operating Activities
- 5013.23
- Cashfrom Investing Activities
- -3211.56
- Cashfrom Financing Activities
- -2969.27
- Net Changein Cash
- -1167.4
- Period
- 2021
- Total Revenue
- 24774.62
- Selling/ General/ Admin Expenses Total
- 8108.66
- Depreciation/ Amortization
- 1055.39
- Other Operating Expenses Total
- 317.35
- Total Operating Expense
- 17540.91
- Operating Income
- 7233.71
- Net Income Before Taxes
- 7343.59
- Net Income
- 5334.84
- Diluted Normalized EPS
- 57.91
- Period
- 2021
- Total Assets
- 33853.99
- Total Liabilities
- 11924.12
- Total Equity
- 21929.87
- Tangible Book Valueper Share Common Eq
- 321.03
- Period
- 2021
- Cashfrom Operating Activities
- 3351.33
- Cashfrom Investing Activities
- 598.69
- Cashfrom Financing Activities
- -1364.81
- Net Changein Cash
- 2583.09
- Period
- 2020
- Total Revenue
- 23098.51
- Selling/ General/ Admin Expenses Total
- 7099.39
- Depreciation/ Amortization
- 966.71
- Other Operating Expenses Total
- 364.07
- Total Operating Expense
- 19190
- Operating Income
- 3908.51
- Net Income Before Taxes
- 3743.04
- Net Income
- 2845.14
- Diluted Normalized EPS
- 49.38
- Period
- 2020
- Total Assets
- 28927.74
- Total Liabilities
- 12103.07
- Total Equity
- 16824.67
- Tangible Book Valueper Share Common Eq
- 231.4
- Period
- 2020
- Cashfrom Operating Activities
- 4381.28
- Cashfrom Investing Activities
- -1567.64
- Cashfrom Financing Activities
- -1947.18
- Net Changein Cash
- 871.24
- Period
- 2019
- Total Revenue
- 19563.55
- Selling/ General/ Admin Expenses Total
- 5628.36
- Depreciation/ Amortization
- 667.95
- Other Operating Expenses Total
- 338.59
- Total Operating Expense
- 16348.13
- Operating Income
- 3215.42
- Net Income Before Taxes
- 3091.35
- Net Income
- 2364.73
- Diluted Normalized EPS
- 41.76
- Period
- 2019
- Total Assets
- 26454.36
- Total Liabilities
- 12563.58
- Total Equity
- 13890.78
- Tangible Book Valueper Share Common Eq
- 184.04
- Period
- 2019
- Cashfrom Operating Activities
- 1650.97
- Cashfrom Investing Activities
- -2902.59
- Cashfrom Financing Activities
- 1919.06
- Net Changein Cash
- 665.64
- Period
- 2024-12-31
- Total Revenue
- 7978.52
- Selling/ General/ Admin Expenses Total
- 1131.55
- Depreciation/ Amortization
- 418.53
- Other Operating Expenses Total
- 1903.75
- Total Operating Expense
- 6769.24
- Operating Income
- 1209.28
- Net Income Before Taxes
- 1199.85
- Net Income
- 845.81
- Diluted Normalized EPS
- 14.56
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7796.07
- Selling/ General/ Admin Expenses Total
- 1109.48
- Depreciation/ Amortization
- 382.28
- Other Operating Expenses Total
- 1910.18
- Total Operating Expense
- 6612.21
- Operating Income
- 1183.86
- Net Income Before Taxes
- 1207.46
- Net Income
- 817.38
- Diluted Normalized EPS
- 14
- Period
- 2024-09-30
- Total Assets
- 48094.45
- Total Liabilities
- 17216.06
- Total Equity
- 30878.39
- Tangible Book Valueper Share Common Eq
- 462.63
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 653.08
- Cashfrom Investing Activities
- -708.22
- Cashfrom Financing Activities
- 545.22
- Net Changein Cash
- 510.88
- Period
- 2024-06-30
- Total Revenue
- 7567.02
- Selling/ General/ Admin Expenses Total
- 1071.95
- Depreciation/ Amortization
- 404.18
- Other Operating Expenses Total
- 1802.82
- Total Operating Expense
- 6351.63
- Operating Income
- 1215.39
- Net Income Before Taxes
- 1323.89
- Net Income
- 919.22
- Diluted Normalized EPS
- 15.69
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 7580.15
- Selling/ General/ Admin Expenses Total
- 1026.32
- Depreciation/ Amortization
- 354.33
- Other Operating Expenses Total
- 1805.86
- Total Operating Expense
- 6369.5
- Operating Income
- 1210.65
- Net Income Before Taxes
- 1229.9
- Net Income
- 908.75
- Diluted Normalized EPS
- 17.1
- Period
- 2024-03-31
- Total Assets
- 45071.51
- Total Liabilities
- 15228.71
- Total Equity
- 29842.8
- Tangible Book Valueper Share Common Eq
- 439.74
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2434.52
- Cashfrom Investing Activities
- -4255.95
- Cashfrom Financing Activities
- 800.42
- Net Changein Cash
- -1006.84
- Period
- 2023-12-31
- Total Revenue
- 7351.78
- Selling/ General/ Admin Expenses Total
- 989.68
- Depreciation/ Amortization
- 423.27
- Other Operating Expenses Total
- 1610.22
- Total Operating Expense
- 6173.74
- Operating Income
- 1178.04
- Net Income Before Taxes
- 1262.42
- Net Income
- 936.29
- Diluted Normalized EPS
- 16.04
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Aurobindo Pharma Technical
Moving Average
SMA
- 5 Day1213.37
- 10 Day1203.97
- 20 Day1211.08
- 50 Day1158.6
- 100 Day1180.12
- 300 Day1297.91
Aurobindo Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1201.85
- -15.15
- -1.24
- 1592.55
- 994.35
- 69803.65
- Pfizer
- 4412.6
- -43.65
- -0.98
- 6452.85
- 3742.9
- 20156.11
- Astrazeneca Pharma India
- 7839.35
- -108.25
- -1.36
- 9199
- 5180.6
- 19598.38
- Neuland Laboratories
- 11053.2
- -817.15
- -6.88
- 18089.55
- 5557
- 14181.14
- Unichem Laboratories
- 587.75
- 1.8
- 0.31
- 949.85
- 507.2
- 4137.03
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 21.07
- 2.36
- 14.22
- 12.72
- Pfizer
- 36.86
- 5.62
- 18.43
- 24.05
- Astrazeneca Pharma India
- 130.35
- 27.52
- 20.1
- 10.27
- Neuland Laboratories
- 69.97
- 9.3
- 17.29
- 14.2
- Unichem Laboratories
- -
- 1.77
- -2.1
- -3.99
Aurobindo Pharma Shareholding
Shareholding Pattern
*Promoter pledging: 8.77%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results
- 06-Feb-25
- Quarterly Results
- 09-Nov-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 18-Jul-24
- Buy Back of Shares
- 25-May-24
- Audited Results
- 10-Feb-24
- Quarterly Results & Interim Dividend
- 09-Nov-23
- Quarterly Results & Interim Dividend
- 12-Aug-23
- Quarterly Results
- 27-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 20-Mar-25
- 13-Feb-25
- POM
- 29-Aug-24
- 31-Jul-24
- AGM
- 28-Mar-24
- 22-Feb-24
- POM
- 28-Dec-23
- 24-Nov-23
- POM
- 25-Aug-23
- 28-Jul-23
- AGM
- 23-Mar-23
- 17-Feb-23
- POM
- 02-Aug-22
- 07-Jul-22
- AGM
- 12-Feb-22
- 12-Jan-22
- POM
- 26-Aug-21
- 03-Aug-21
- AGM
- 27-Aug-20
- 03-Aug-20
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-Feb-24
- 20-Feb-24
- 20-Feb-24
- 1.5
- 02-Nov-23
- 20-Nov-23
- 20-Nov-23
- 3
- 03-Feb-23
- 17-Feb-23
- 17-Feb-23
- 3
- 20-May-22
- 07-Jun-22
- 06-Jun-22
- 4.5
- 09-Feb-22
- 21-Feb-22
- 18-Feb-22
- 1.5
- 08-Nov-21
- 18-Nov-21
- 17-Nov-21
- 1.5
- 12-Aug-21
- 30-Aug-21
- 27-Aug-21
- 1.5
- 10-Feb-21
- 23-Feb-21
- 22-Feb-21
- 1.5
- 11-Nov-20
- 24-Nov-20
- 23-Nov-20
- 1.25
- 12-Aug-20
- -
- 21-Aug-20
- 1.25


